HSBC Initiates Coverage of Biogen (BIIB) with Buy Recommendation
Nasdaq Fintel reports that on September 6, 2023, HSBC initiated coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation.
Analyst Price Forecast Suggests 27.90% Upside
As of August 30, 2023, the average one-year price target for Biogen is 337.48. The forecasts range from a low of 271.69 to a high of $525.00. The average price target represents an increase of 27.90% from its latest reported closing price of 263.85.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Biogen is 9,565MM, a decrease of 4.08%. The projected annual non-GAAP EPS is 15.98.
What is the Fund Sentiment?
There are 1955 funds or institutions reporting positions in Biogen. This is a decrease of 34 owner(s) or 1.71% in the last quarter. Average portfolio weight of all funds dedicated to BIIB is 0.34%, a decrease of 2.46%. Total shares owned by institutions decreased in the last three months by 0.15% to 138,227K shares. The put/call ratio of BIIB is 0.78, indicating a bullish outlook.